ESPR•benzinga•
Goldman Sachs Maintains Neutral on Esperion Therapeutics, Lowers Price Target to $3
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 17, 2025 by benzinga